Recent advances in cryo technology have yielded positive results in the treatment of arrhythmias with cold energy delivered through a 7 French (Fr) catheter. Freezor®, a cryocatheter from CryoCath Technologies, has been in clinical use in Europe for the past two years. In that time, it has established a record of safety and effectiveness in the treatment of arrhythmias, particularly in peri-nodal procedures. The technology has also proven itself in an Investigational Device Exemption study held at 10 centers in the United States and 3 in Canada.
Pending FDA approval, Freezor® is expected to be available in the U.S. this year. With its demonstrated safety profile — especially important when working around the atrioventricular (AV) node — Freezor® represents a new paradigm in treatment alternatives for electrophysiologists.
The Biology of CryoTherapy1
Cryotherapy is the use of cooling and freezing in living tissue to affect cellular function and activity. To produce cryotherapeutic temperatures, heat energy is removed from the tissue, rather than “injecting” cold energy into the tissue. Multiple factors influence the effectiveness of catheter-based cryotherapy. Chief among these are: 1) tip contact [to remove heat from the tissue, the catheter tip must be in contact with the tissue]; 2) tip temperature [the catheter tip temperature applied determines if the cells are subjected to hypothermia or killed]; and 3) freeze duration [longer freeze times will cause more tissue damage].
Figure 1
|  | | The CryoTherapy Zone: Understanding the dynamic thermal gradient. A cryotherapy zone can be seen in both cryomapping and cryoablation procedures. The zone is thermally dynamic over time as cells that remain in above zero temperature gradients display a transient electrical effect while cells experiencing sub-zero temperatures are ablated.
|
During cryoablation, the removal of heat from the tissue creates a temperature gradient that extends from the catheter tip to the edge of the “cryotherapy zone”. At the tip/tissue interface of the catheter, the cryotherapy temperature can be either -30ºC and -75ºC, depending on the type of intervention (cryomapping or cryoablation). The temperature in the cryotherapy zone ranges from the sub-zero cryogenic temperature at the tip-tissue interface to body temperature at sites distant from the catheter tip. This zone is “dynamic” as it expands during freezing and shrinks upon re-warming. In living tissue, vascularity always provides a heat source and will, as a result, cause local variations in temperature (Figure 1).
Cryomapping and Cryoablation Mechanisms
Catheter-based cryotherapy includes two complementary procedures: cryomapping, which allows for the confirmation of target sites; and cryoablation, which destroys the cells responsible for the arrhythmia. When cells are cooled below body temperature, a series of events occurs. Beginning at a tissue temperature around 32ºC, the cell membranes lose transport capability, and ion pump activity decreases. These changes result in a decrease in the rate of spontaneous depolarization, loss of resting membrane potential, a decrease in action potential amplitude and an increase in action potential duration, along with a corresponding increase in refractory period. Conduction velocity slows and local conduction block in the region being cooled may occur. As long as cell temperatures do not fall below CryoCath Technologies | - CryoCath is a leading medical technology company in the development and commercialization of cryotherapy catheters and surgical probes for the treatment of cardiovascular disease. Traditionally, the use of freezing temperatures for therapeutic purposes has been limited by the inability to deliver the treatment in a minimally invasive manner. CryoCath has overcome this obstacle by developing super-thin, flexible, steerable, catheters to deliver cold therapy safely and effectively. For more on CryoCath’s electrophysiology and cardiac surgery products, visit: www.cryocath.com
As part of NASPE 2003, held in Washington, D.C. from May 14 to 17, CryoCath will host a symposium for physicians interested in learning more about treating patients with cryotherapy.
For information on the cryotherapy symposium, visit www.cryocath.com and click on “Events”. While at NASPE, you can visit CryoCath at booth number #483.
CryoCath Electrophysiology Products
Freezor®
The flagship EP product, Freezor™ is a 7 French flexible, single-use, minimally invasive cryocatheter designed to create focal lesions to treat arrhythmias in peri-nodal accessory pathways and AVNRT pathways where precision is of crucial importance. Freezor™ is in use in major centers in Europe and around the world and will soon be available in the United States. In Europe, a 7 French Freezor™ Xtra is also available with more cooling power. European centers can also look forward to CryoCathís pending release of Freezor™ MAX, a 9 French 8 mm catheter with very substantial cooling power for treating arrhythmias.
Arctic Circler™
Currently available in Europe, the Arctic Circler™ catheter uses the same cryoconsole and platform technology as Freezor™ to treat atrial fibrillation originating in the pulmonary veins. Arctic Circler™ is a cryotherapy tool designed to challenge the traditional palliative-only treatments that rely on medication.
In Development
Catheters in development include Frostline* Linear CryoAblation for procedures requiring linear lesions in the epicardial space and Arctic Circler™ Balloon to help isolate the pulmonary vein.
Caution: Investigational devices, limited by United States federal law to investigational use.
CryoCath Cardiac Surgery
SurgiFrost™
The SurgiFrost™ cryoablation system provides a safe and effective option in the treatment of arrhythmias during cardiac surgery.
The malleable, single-use probe allows the surgeon to create the complete Maze III lesion set from an endocardial or epicardial approach, in a beating or stopped heart. The Argon-powered (-160ºC) probe delivers fast, transmural ablations in a simple and safe system.
|
freezing these changes are reversible: cells recover normal function when they are warmed. In the electrophysiology laboratory, these temporary changes in excitability and conduction can be easily detected as local increases in refractory period and/or transient local conduction block. For example, in a patient with Wolff-Parkinson-White syndrome, cryomapping near the site of the accessory pathway can cause temporary disappearance of the delta wave during sinus rhythm. Another example would be cryomapping in the region of the slow AV nodal pathway in a patient with AV nodal reentrant supraventricular tachycardia (SVT), which can cause temporary block in the slow pathway and render the SVT non inducible. Cryomapping used in this fashion can help to identify appropriate sites where cryoablation is likely to be successful in permanently abolishing the target arrhythmia. Conversely, cryomapping may be used to identify sites, for example near the compact AV node or His bundle, where ablation is likely to have unintended consequences, such as the production of complete AV block.
Ice Formation
When cell temperatures are lowered below the freezing point, ice formation occurs inside and outside the cell, resulting in permanent tissue damage. At fast cooling rates — that is, at or very close to the tip-tissue interface— water cannot leave the cell fast enough; therefore, ice forms within the cell. Intracellular ice destroys internal cellular structure, resulting in cell death. At slower cooling rates — affecting cells farther away from the tip-tissue interface — ice crystals form in the extracellular space, creating an osmotic imbalance that causes the cell to dehydrate and shrink. As intracellular ice crystals form, they cause a rupture of the cell membrane, resulting in cell death.
Thawing
Significant tissue destruction also occurs during thawing. As the temperature rises from -75ºC to 37ºC, small ice crystals thaw and reform into larger crystals and large crystals reform as small ones; throughout the thawing process, the overall volume of crystallization diminishes as the temperature rises. This reorganization of crystal size and shape causes cell membrane disruption that results in cell death.
Post-Thaw
Cells are also killed after being exposed to the freeze/thaw cycle. This cell destruction occurs via two mechanisms: necrosis and apoptosis. The first of these, necrosis (or cell rupture), is delayed death whose occurrence peaks after six hours following thawing. Necrosis occurs in tissue that has been frozen or subjected to sub-zero temperatures. It is an event that completes the cryoablation process by filling in the periphery of the lesion. It does not cause new cell damage and does not increase the size of the lesion.
The second post-thaw cell death mechanism is apoptosis (or cell suicide). The freeze affects genetic architecture, causing the cell to self-destruct. The occurrence of cell suicide peaks 12 hours following thawing in cells that were partially frozen or severely stressed without experiencing ice formation. It is an event that completes the cryoablation process by filling in the periphery of the lesion. Apoptosis does not cause new cell damage and does not increase the size of lesion.
Cryolesions are sharply demarcated and heal more rapidly than lesions caused by radiofrequency current, leaving a dense scar that does not affect the electrical activity of surrounding tissue. Preclinical studies have demonstrated minimal endothelial disruption with cryoablation and virtually no overlying thrombus formation.2 Furthermore, sudden dramatic rises in impedance at the tip/tissue interface do not occur with cryoablation as sometimes happens with radiofrequency ablation. This translates into a much lower risk of barotrauma and cardiac perforation.
Cryoadhesion
As the tissue is cooled below freezing, the tip of the catheter adheres to it; once the tip has adhered, it does not dislodge. Cryoadhesion provides greater catheter stability, especially important when working around critical structures such as the AV node. In addition, the catheter tip will not dislodge with the termination of the tachycardia or with pacing maneuvers.
How the CryoTherapy System Works
The cryoablation catheter manufactured by CryoCath Technologies is a 7F steerable multipolar catheter similar in appearance and handling characteristics to a standard radiofrequency ablation catheter, though its mode of action is quite different. Pressurized liquid nitrous oxide is delivered to the tip of the catheter from the cryoconsole through an ultra-fine, robust injection tube. Before it is released into the tip expansion chamber, it is further pressurized as it encounters a restriction tube at the distal end of the injection tube. The restriction tube is designed to maximize the temperature drop of the refrigerant prior to entering the expansion chamber. Cooling occurs as a result of the Joule Thompson effect (whereby a decrease in pressure brings about a drop in temperature). As the refrigerant enters the tip expansion chamber (maintained under vacuum) and comes in contact with the tip surface, a liquid-to-gas phase change occurs. The cold liquid refrigerant evaporates as it absorbs heat from the tip that is in contact with the tissue. While tissue and blood flow act as a heat source, the tip of the catheter acts as a heat sink. The warmed vapor is returned to the console through a lumen maintained under vacuum. While there is minimal ice formation around the tip of the catheter, it quickly melts away as soon as the cryo application is terminated; therefore, it poses no threat of breaking off and occluding small vessels.
Multiple features are built into the catheter-console system to ensure safety. The system is always under vacuum — a failsafe that enables it to detect fluid ingress and stop the procedure. Multiple connector checks confirm that everything is properly connected prior to use. A sophisticated algorithm monitors the flow of the refrigerant and return vapor and halts the injection if the flow surpasses normal parameters. A vent system in the console draws back the liquid refrigerant after each injection.
The Clinical Utility of Cryoablation
Of the many hundreds of thousands of catheter ablation procedures performed annually in patients with supraventricular tachycardia, approximately 150,000 involve ablation near the AV node and His bundle. This group is comprised of individuals with AV nodal reentrant supraventricular tachycardia, patients with mid-septal, antero-septal or para-Hissian accessory pathways and others with focal atrial tachycardia arising near the compact AV node. During radiofrequency catheter ablation in the peri-nodal region, application of radiofrequency (RF) current usually provokes an accelerated junctional rhythm that impairs one’s ability to monitor anterograde AV conduction during the ablation. Transient AV block, which can be difficult to detect, occurs in 3–5% of patients undergoing such procedures. Even if radiofrequency current application is terminated promptly when AV block is first detected, 1–2% of patients will be left with persistent complete or high-grade AV block, necessitating implantation of a permanent pacemaker. This is a dreaded complication, particularly in young patients whose target arrhythmia may be troublesome but not life-threatening. In contrast to radiofrequency catheter ablation, cryoablation in the peri-nodal region does not provoke accelerated junctional rhythm, enabling the electrophysiologist to monitor anterograde AV conduction closely throughout the ablation procedure. If AV block appears during cryoablation, it uniformly resolves, usually within a few seconds, as soon as cryoablation is halted. This feature, along with the exceptional catheter stability that stems from cryoadhesion, helps to make cryoablation in the peri-nodal region effective and extremely safe. Indeed, over 600 patients worldwide have undergone successful cryoablation in the peri-nodal region, and not a single case of inadvertent AV block requiring permanent pacemaker implantation has been reported. For patients undergoing ablation in the peri-nodal region, where one faces a significant risk of inadvertent AV block, catheter cryoablation offers an effective and very safe alternative.3 |
